Pharmacokinetics of quinine in chronic liver disease.
- 1 November 1995
- journal article
- Published by Wiley
- Vol. 40 (5) , 494-497
- https://doi.org/10.1111/j.1365-2125.1995.tb05795.x
Abstract
The pharmacokinetics of quinine were investigated in a) six healthy male Thai subjects, and b) nine male Thai patients with a moderate degree of chronic liver disease, after a single oral dose of 600 mg quinine sulphate. tmax and t1/2.2 were significantly prolonged in patients (median [range] tmax 2 [1-5] vs 1.6 [0.8-2] h; t1/2,z 23.4 [17.4-41.7] vs 9.7 [7.8-17.2] h), and Vz/F was significantly larger (median [range] 4.21 [2.33-15.87] vs 2.78 [1.49-3.38] 1 kg-1). Median (range) concentration of the plasma unbound Qn fraction collected from the patients at 4 h after drug administration was 17 (8.4-17.8)% of total drug concentration.Keywords
This publication has 18 references indexed in Scilit:
- Digitoxin and its metabolites in patients with liver cirrhosisEuropean Journal of Drug Metabolism and Pharmacokinetics, 1993
- Cardiac effects of antimalarial treatment with halofantrineThe Lancet, 1993
- The pharmacokinetics of quinine in patients with hepatitis.British Journal of Clinical Pharmacology, 1993
- Pharmacokinetics of metoclopramide in patients with liver cirrhosis.British Journal of Clinical Pharmacology, 1991
- Serum albuminHepatology, 1988
- Quinine disposition kinetics.British Journal of Clinical Pharmacology, 1983
- Quinine pharmacokinetics and toxicity in cerebral and uncomplicated falciparum malariaThe American Journal of Medicine, 1982
- Disease-induced Changes in the Plasma Binding of Basic DrugsClinical Pharmacokinetics, 1980
- The treatment of severe falciparum malariaTransactions of the Royal Society of Tropical Medicine and Hygiene, 1977
- Quantitation of portasystemic shunting from the splenic and mesenteric beds in alcoholic liver diseaseThe American Journal of Medicine, 1972